Cargando…

Risikoidentifikation bei Polypharmazie in einer Pflegeheimpopulation

INTRODUCTION: Multimorbidity in old age is one reason for intensified pharmacotherapy. At the same time, an increase in medications could augment multimorbidity, especially when drug interactions leading to undesired drug effects occur. METHODS: In this cross-sectional study 918 mentally ill seniors...

Descripción completa

Detalles Bibliográficos
Autores principales: Specka, Michael, Groll, Maria, Scherbaum, Norbert, Wiltfang, Jens, Benninghoff, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064868/
https://www.ncbi.nlm.nih.gov/pubmed/33570659
http://dx.doi.org/10.1007/s00391-021-01850-6
Descripción
Sumario:INTRODUCTION: Multimorbidity in old age is one reason for intensified pharmacotherapy. At the same time, an increase in medications could augment multimorbidity, especially when drug interactions leading to undesired drug effects occur. METHODS: In this cross-sectional study 918 mentally ill seniors living in nursing homes (mean age 79.3 (±11.6) years; 31.8% male) were included. Two different approaches to assess risks due to pharmacotherapy were applied: first mediQ, an online-based clinical decision support software (CDSS) and the PRISCUS list, which indicates potentially inappropriate medication. PRISCUS is the German equivalent to the American Geriatrics Society Beers criteria. RESULTS: Of the patients in the study 76.3% were at clinical risk, 2.2% at potentially high risk for drug interactions regarding the entire medication as tested by mediQ, and about 25% of the studied population received potentially inappropriate medication according to the PRISCUS list. CONCLUSION: This difference clearly underlines the cumbersome complexity of identifying patients at risk by using these exemplary devices. The focus of avoiding undesired drug side effects should be taking medication only after thorough verification of clinical indications and under close monitoring. The CDSS or negative lists may support this process.